Showing results (241-250 of 297) with videos related to
Sort By:
Pageof 30
Cancer Discovery|August 4, 2022
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid TransformationAnna Yeaton, Geraldine Cayanan, Sanam Loghavi, et al.Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.Haematologica|December 12, 2024
Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasmsJayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, et al.The Lancet. Haematology|December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trialNicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.British Journal of Haematology|September 22, 2025
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemiaWei-Ying Jen, Guilin Tang, Eitan Kugler, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative AnalysisNaval Daver, Jayastu Senapati, Hagop M Kantarjian, et al.Cancers|November 13, 2025
Mutational Landscape and Clinical Impact of SPEN Mutations in Patients with Chronic Lymphocytic LeukemiaPriyatharsini Nirmalanantham, Andrés E Quesada, Anindita Ghosh, et al.Pathology|March 18, 2023
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphomaSiba El Hussein, L Jeffrey Medeiros, Kirill A Lyapichev, et al.Journal of Hematology & Oncology|November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.Pageof 30